Search results
Showing 1 to 4 of 4 results for teduglutide
Evidence-based recommendations on teduglutide (Resvestive) for treating short bowel syndrome in people 1 year and above.
Teduglutide for treating short bowel syndrome (terminated appraisal) (TA690)
This guidance has been updated and replaced by NICE technology appraisal guidance TA804.
NICE recommends potentially life-changing treatment for people with short bowel syndrome
A potentially life-changing treatment has been recommended for people with short bowel syndrome who are aged 1 year and above after NICE published final draft guidance today (01 June 2022)